This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of 11.11% and 11.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 5.66% and 1.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Tops Q2 Earnings Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 9.13% and 0.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
by Zacks Equity Research
Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
Reasons to Add Cencora (COR) Stock in Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 16.84% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
by Zacks Equity Research
Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Improving membership levels, strategic acquisitions, expanding government business, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.
Elevance Health (ELV) Enhances Whole Health With Paragon Buyout
by Zacks Equity Research
Elevance Health (ELV) agrees to acquire Paragon Healthcare, boosting its capabilities in specialty pharmacy.
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
by Zacks Equity Research
Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Here's Why You Should Retain Teladoc (TDOC) Stock for Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.